Cambridge biotech Curis Inc. is lined up to receive a $3 million milestone payment after the company marked its fifth patient treatment in a Phase 1 clinical trial led by licensee Debiopharm SA.
The trial tested Debio 0932, formerly CUDC-305, a small molecule heat shock protein 90 inhibitor intended to treat lymphoma and advanced solid tumors. The initial part of the trial tests safety and tolerability, while the second part, Phase 1b, measures the dose level of Debio 0932.
Curis, a cancer-focused company, has earned a total of about $13 million in milestone payments from the collaboration with Debiopharm.
Curis (Nasdaq: CRIS) announced last month that GDC-0449, its hedgehog pathway inhibitor to fight cancer, failed to meet its Phase 2 clinical trial goals, which it initiated with Roche Holding AG and Genentech Inc.